Worsening in oxygen saturation and exercise capacity predict adverse outcome in patients with Eisenmenger syndrome

International Journal of Cardiology

Volumn 168, Issue 2, 2013, Pages 1386-1392

  Van De Bruaene, Alexander ^a   De Meester, Pieter ^a   Voigt, Jens Uwe ^a   Delcroix, Marion ^a   Pasquet, Agnes ^b   De Backer, Julie ^c   De Pauw, Michel ^c   Naeije, Robert ^d   Vachiéry, Jean Luc ^d   Paelinck, Bernard P ^e   Morissens, Marielle ^f   Budts, Werner ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d ERASME HOSPITAL   (Belgium)

^e ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^f BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Eisenmenger syndrome; Exercise capacity; Outcome; Oxygen saturation; Pulmonary hypertension

Indexed keywords

ALLOPURINOL; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CARDIOVASCULAR AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; OXYGEN; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN;

ADULT; ADVERSE OUTCOME; ARTICLE; BIOCHEMISTRY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; DISEASE EXACERBATION; ECHOCARDIOGRAPHY; EISENMENGER COMPLEX; EXERCISE; EXERCISE TEST; FEMALE; FOLLOW UP; HEART RIGHT VENTRICLE FAILURE; HEART TRANSPLANTATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; MORTALITY; OUTCOME ASSESSMENT; OXYGEN SATURATION; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; REST; SENSITIVITY AND SPECIFICITY;

EISENMENGER SYNDROME; EXERCISE CAPACITY; OUTCOME; OXYGEN SATURATION; PULMONARY HYPERTENSION;

ADULT; DISEASE PROGRESSION; EISENMENGER COMPLEX; EXERCISE; EXERCISE TOLERANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; OXYGEN CONSUMPTION; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84885331033     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.12.021     Document Type: Article

References (38)

1. Engelfriet PM, Duffels MG, Moller T, et al. Pulmonary arterial Hypertension In adults born with a heart septal defect: the euro heart survey on adult congenital heart disease. Heart 2007;93:682-7.
2. Diller GP, Gatzoulis MA. Pulmonary vascular disease In adults with congenital heart disease. Circulation 2007;115:1039-50.
3. Wood P. The eisenmenger syndrome or pulmonary Hypertension with reversed central shunt. Br Med J 1958;2:755-62.
4. Niwa K, Perloff JK, Kaplan S, Child JS, Miner PD. Eisenmenger syndrome In adults: ventricular septal defect, truncus arteriosus, univentricular heart. J Am Coll Cardiol 1999;34:223-32.
5. Cantor WJ, Harrison DA, Moussadji JS, et al. Determinants of survival and length of survival In adults with Eisenmenger syndrome. Am J Cardiol 1999;84:677-81.
6. Daliento L, Somerville J, Presbitero P, et al. Eisenmenger syndrome. Factors relating to deterioration and death. Eur Heart J 1998;19:1845-55.
7. Van De Bruaene A, Delcroix M, Pasquet A, et al. Iron deficiency Is associated with adverse outcome In Eisenmenger patients. Eur Heart J 2011;32:2790-9.
8. Diller GP, Dimopoulos K, Broberg CS, et al. presentation, survival prospects, and predictors of death In eisenmenger syndrome: a combined retrospective and case-control study. Eur Heart J 2006;27:1737-42.
9. Van De Bruaene A, De Meester P, Voigt JU, et al. Right ventricular function In patients with Eisenmenger syndrome. Am J Cardiol 2012;109:1206-11.
10. Diller GP, Alonso-Gonzalez R, Kempny A, et al. B-type natriuretic peptide concentrations In contemporary eisenmenger syndrome patients: predictive value and response to disease targeting therapy. Heart 2012;98:736-42.
11. HopkinsWE, Ochoa LL, Richardson GW, Trulock EP. Comparison of the hemodynamics and survival of adults with severe primary pulmonary Hypertension or eisenmenger syndrome. J Heart Lung Transplant 1996;15:100-5.
12. Sakazaki H, Niwa K, Nakazawa M, et al. Clinical features of adult patients with Eisenmenger's syndrome In Japan and Korea. Int J Cardiol 2013;167(1):205-9.
13. GalieN, BeghettiM,GatzoulisMA, et al. Bosentan therapy In patientswith Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006;114:48-54.
14. Dimopoulos K, Inuzuka R, Goletto S, et al. Improved survival among patients with eisenmenger syndrome receiving advanced therapy for pulmonary arterial Hypertension. Circulation 2010;121:20-5.
15. Galie N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial Hypertension. The task force on diagnosis and treatment of pulmonary arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004;25:2243-78.
16. Van de Bruaene A, Delcroix M, Pasquet A, et al. The Belgian Eisenmenger Syndrome Registry: Implications for treatment strategies? Acta Cardiol 2009;64:447-53.
17. Aha medical/scientific statement. 1994 revisions to classification of functional capacity and objective assessment of patients with diseases of the heart. Circulation 1994;90: 644-5.
18. Saha A, Balakrishnan KG, Jaiswal PK, et al. Prognosis for patients with Eisenmenger syndrome of various aetiology. Int J Cardiol 1994;45:199-207.
19. Oya H, Nagaya N, Uematsu M, et al. Poor prognosis and related factors In adults with Eisenmenger syndrome. Am Heart J 2002;143:739-44.
20. Sitbon O, HumbertM, Nunes H, et al. Long-termIntravenous epoprostenol Infusion In primary pulmonary Hypertension: prognostic factors and survival. J Am Coll Cardiol 2002;40:780-8.
21. Diller GP, Alonso-Gonzalez R, Dimopoulos K, et al. disease targeting therapies In patients with Eisenmenger syndrome: response to treatment and long-term efficiency. Int J Cardiol 2013;167(3):840-7.
22. Van deVeerdonkM,Kind T,Marcus JT, et al. Progressive right ventricular dysfunction In patients with pulmonary arterial Hypertension responding to therapy. J Am Coll Cardiol 2012;58:2511-9.
23. Kaya MG, Lam YY, Erer B, et al. Long-term effect of bosentan therapy on cardiac function and symptomatic benefits In adult patients with Eisenmenger syndrome. J Card Fail 2012;18:379-84.
24. Christensen DD,McConnellME, BookWM,MahleWT. Initial experiencewith bosentan therapy In patients with the Eisenmenger syndrome. Am J Cardiol 2004;94:261-3.
25. Apostolopoulou SC, Manginas A, Cokkinos DV, Rammos S. Long-term oral bosentan treatment In patients with pulmonary arterial Hypertension related to congenital heart disease: a 2-year study. Heart 2007;93:350-4.
26. D'Alto M, Vizza CD, Romeo E, et al. Long term effects of bosentan treatment In adult patients with pulmonary arterial Hypertension related to congenital heart disease (Eisenmenger Physiology): safety, tolerability, clinical, and haemodynamic effect. Heart 2007;93:621-5.
27. Schulze-Neick I, Gilbert N, Ewert R, et al. Adult patients with congenital heart disease and pulmonary arterial Hypertension: first open prospective Multicenter Study of Bosentan Therapy. Am Heart J 2005;150:716.
28. Gatzoulis MA, Beghetti M, Galie N, et al. Longer-term bosentan therapy Improves functional capacity In eisenmenger syndrome: results of the breathe-5 open-label extension study. Int J Cardiol 2008;127:27-32.
29. Garg N, Sharma MK, Sinha N. Role of oral sildenafil In severe pulmonary arterial Hypertension: clinical efficacy and dose response relationship. Int J Cardiol 2007;120: 306-13.
30. Chau EM, Fan KY, ChowWH. Effects of chronic sildenafil In patients with eisenmenger syndrome versus Idiopathic pulmonary arterial Hypertension. Int J Cardiol 2007;120: 301-5.
31. Zhang ZN, Jiang X, Zhang R, et al. Oral sildenafil treatment for eisenmenger syndrome: a prospective, open-label, multicentre study. Heart 2011;97:1876-81.
32. Mukhopadhyay S, Nathani S, Yusuf J, Shrimal D, Tyagi S. Clinical efficacy of phosphodiesterase-5 Inhibitor tadalafil In eisenmenger syndrome-a randomized, placebo-controlled, double-blind crossover study. Congenit Heart Dis 2011;6:424-31.
33. Galie N, Rubin L, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial Hypertension with bosentan (early study): a double-blind, randomised controlled trial. Lancet 2008;371:2093-100.
34. Diller GP, Dimopoulos K, Okonko D, et al. Exercise Intolerance In adult congenital heart disease: comparative severity, correlates, and prognostic Implication. Circulation 2005;112:828-35.
35. Kempny A, Dimopoulos K, Uebing A, et al. Reference values for exercise limitations among adultswith congenital heart disease. Relation to activities of daily life-single centre experience and review of published data. Eur Heart J 2011;33:1386-96.
36. Muller J, Hess J, Hager A. Exercise performance and quality of life Is more Impaired In Eisenmenger syndrome than In complex cyanotic congenital heart disease with pulmonary stenosis. Int J Cardiol 2011;150:177-81.
37. Raphael C, Briscoe C, Davies J, et al. Limitations of the new york heart Association functional classification system and self-reported walking distances In chronic heart failure. Heart 2007;93:476-82.
38. Moons P, Van Deyk K, De Geest S, Gewillig M, BudtsW. Is the severity of congenital heart disease associated with the quality of life and perceived health of adult patients? Heart 2005;91:1193-8